Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

131.60
-0.9600-0.72%
Post-market: 131.20-0.4000-0.30%17:42 EDT
Volume:706.97K
Turnover:92.77M
Market Cap:13.21B
PE:28.18
High:133.75
Open:130.81
Low:130.00
Close:132.56
52wk High:160.18
52wk Low:84.23
Shares:100.36M
Float Shares:98.00M
Volume Ratio:0.78
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.67
EPS(LYR):4.67
ROE:16.38%
ROA:9.53%
PB:4.06
PE(LYR):28.18

Loading ...

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Benzinga
·
Feb 13

Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says

MT Newswires Live
·
Feb 13

Neurocrine (NBIX) Receives a Buy from Jefferies

TIPRANKS
·
Feb 12

Stock Track | Neurocrine Biosciences Plummets 5.65% Intraday Amid Series of Analyst Price Target Reductions

Stock Track
·
Feb 12

Wedbush Remains a Buy on Neurocrine (NBIX)

TIPRANKS
·
Feb 12

Canaccord Genuity Reaffirms Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Feb 12

Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating

MT Newswires Live
·
Feb 12

Neurocrine Is Maintained at Buy by Needham

Dow Jones
·
Feb 12

Neurocrine price target lowered to $192 from $198 at H.C. Wainwright

TIPRANKS
·
Feb 12

Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures

TIPRANKS
·
Feb 12

Neurocrine Biosciences: Durable Franchise Momentum and Pipeline Investment Support Buy Rating

TIPRANKS
·
Feb 12

Neurocrine Biosciences Q4 GAAP other income rises 38% to USD 28.5 million

Reuters
·
Feb 12

BRIEF-Neurocrine Biosciences Q4 Adjusted EPS USD 1.88 Vs. IBES Estimate USD 1.88

Reuters
·
Feb 12

Neurocrine Biosciences Q4 Net Income USD 153.7 Million

THOMSON REUTERS
·
Feb 12

Neurocrine Biosciences Q4 Adjusted EPS USD 1.88 VS. Ibes Estimate USD 1.88

THOMSON REUTERS
·
Feb 12

Neurocrine Biosciences Inc: Q4 Total REV $805.5 Mln

THOMSON REUTERS
·
Feb 12

Neurocrine Biosciences Inc - Ingrezza 2026 Sales Guidance Set at $2.7-$2.8 Bln

THOMSON REUTERS
·
Feb 12

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Cardinal Health (CAH)

TIPRANKS
·
Feb 06

Earning Preview: Neurocrine Biosciences Q4 revenue is expected to increase by 26.07%, and institutional views are positive

Earnings Agent
·
Feb 04

Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update

Simply Wall St.
·
Feb 01